Slingshot AI vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Slingshot AI raised $93M (a16z) for its Ash therapy chatbot with 50K beta users; withdrew from UK over medical device concerns while expanding US CBT-informed AI mental health access.
About
Slingshot AI is a mental health technology company developing AI-powered therapy and emotional support tools designed to expand access to mental health care. Backed by Andreessen Horowitz (a16z), Slingshot has built Ash, a conversational AI therapy chatbot that provides CBT-informed and evidence-based support to users between professional therapy sessions or as a standalone resource for people who cannot access or afford traditional therapy. The company was founded on the premise that the global mental health crisis — characterized by a severe shortage of therapists relative to need — requires AI-enabled solutions to close the access gap.\n\nAsh is designed to conduct structured therapeutic conversations, guide users through mental health exercises, track mood and symptom patterns over time, and provide crisis resources when needed. The platform is built with clinical input and aims to function at the boundary between a mental wellness app and a clinical-grade tool, offering more depth than meditation apps while being accessible without a prescription or insurance. Slingshot has enrolled 50,000+ beta users who have engaged with Ash's conversational therapy features across depression, anxiety, and stress-related concerns.\n\nSlingshot has raised $93M in total funding, backed by a16z and other investors, reflecting strong venture conviction in the mental health AI space despite a complex regulatory environment. The company made a notable decision to withdraw from the UK market in January 2026 over concerns about medical device regulatory requirements — the UK's MHRA was signaling that AI therapy tools would require medical device classification, raising the compliance burden significantly. This withdrawal highlights the tension between the consumer mental health app model and the regulatory frameworks emerging around AI clinical tools, a challenge Slingshot and the broader mental health AI category are actively navigating.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.